Atara Biotherapeutics (ATRA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 8, 2026.

Voting matters and shareholder proposals

• Election of two directors: Anh Co Nguyen, Ph.D. and Nachi Subramanian, both recommended by the board.

• Advisory vote to approve named executive officer compensation.

• Proposal to amend the 2024 Equity Incentive Plan, increasing reserved shares by 400,000.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Proxy holders may vote on other matters arising at the meeting at their discretion.

Board of directors and corporate governance

• Board recommends all proposals, including director nominees and compensation matters.